GlassScriptPhysician profile
Richard Prewitt
NPI 1326052374
$1,035.04
in general payments reported to CMS, 2019-2025
13 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2021: $48.80 · 2022: $187 · 2023: $294 · 2024: $216 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $653.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $652.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $165.41 | 2019-2025 | |
| Edwards Lifesciences Corporation | $136.88 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Abbott Laboratories | $124.38 | 2019 | |
| Amgen INC. | $113.19 | 2022-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $97.39 | 2022-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $89.07 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $83.20 | 2022-2025 | Watchman Flx |
| Novo Nordisk INC | $60.66 | 2022-2024 | Rybelsus, Ozempic, Tresiba |
| Exact Sciences Corporation | $48.89 | 2023-2024 | Cologuard Collection Kit |
| Pfizer INC. | $48.57 | 2022-2024 | |
| Cvrx, INC. | $30.57 | 2022-2025 | Barostim Neo System |
| Kiniksa Pharmaceuticals International, Plc | $22.94 | 2024 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $13.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Prewitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.